HAPLN1 potentiates peritoneal metastasis in pancreatic cancer

The presence of peritoneal metastasis in pancreatic cancers is associated with poor prognosis. Here the authors show that hyaluronan and proteoglycan link protein-1 (HAPLN1) promotes tumour cell plasticity and pro-tumoral immune microenvironment to facilitate peritoneal dissemination in pancreatic cancers. Pancreatic ductal adenocarcinoma (PDAC) frequently metastasizes into the peritoneum, which contributes to poor prognosis. Metastatic spreading is promoted by cancer cell plasticity, yet its regulation by the microenvironment is incompletely understood. Here, we show that the presence of hyaluronan and proteoglycan link protein-1 (HAPLN1) in the extracellular matrix enhances tumor cell plasticity and PDAC metastasis. Bioinformatic analysis showed that HAPLN1 expression is enriched in the basal PDAC subtype and associated with worse overall patient survival. In a mouse model for peritoneal carcinomatosis, HAPLN1-induced immunomodulation favors a more permissive microenvironment, which accelerates the peritoneal spread of tumor cells. Mechanistically, HAPLN1, via upregulation of tumor necrosis factor receptor 2 (TNFR2), promotes TNF-mediated upregulation of Hyaluronan (HA) production, facilitating EMT, stemness, invasion and immunomodulation. Extracellular HAPLN1 modifies cancer cells and fibroblasts, rendering them more immunomodulatory. As such, we identify HAPLN1 as a prognostic marker and as a driver for peritoneal metastasis in PDAC

Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event

Leukocytoclastic vasculitis is a multicausal systemic inflammatory disease of the small vessels, histologically characterized by inflammation and deposition of both nuclear debris and fibrin in dermal postcapillary venules. The clinical picture typically involves palpable purpura of the lower legs and may be associated with general symptoms such as fatigue, arthralgia and fever. Involvement of the internal organs, most notably the kidneys, the central nervous system or the eyes, is possible and determines the prognosis. Oxaliplatin-induced leukocytoclastic vasculitis is a very rare event that limits treatment options in affected patients. We report 2 patients who developed the condition under chemotherapy for advanced rectal and metastatic colon carcinoma, respectively; a termination of the therapy was therefore necessary. While current therapies for colorectal cancer include the combination of multimodal treatment with new and targeted agents, rare and unusual side effects elicited by established agents also need to be taken into account for the clinical management

Impairment of angiogenesis by fatty acid synthase inhibition Involves mTOR malonylation

The role of fatty acid synthesis in endothelial cells (ECs) remains incompletely characterized. We report that fatty acid synthase knockdown (FASNKD) in ECs impedes vessel sprouting by reducing proliferation. Endothelial loss of FASN impaired angiogenesis in vivo, while FASN blockade reduced pathological ocular neovascularization, at >10-fold lower doses than used for anti-cancer treatment. Impaired angiogenesis was not due to energy stress, redox imbalance, or palmitate depletion. Rather, FASNKD elevated malonyl-CoA levels, causing malonylation (a post-translational modification) of mTOR at lysine 1218 (K1218). mTOR K-1218 malonylation impaired mTOR complex 1 (mTORC1) kinase activity, thereby reducing phosphorylation of downstream targets (p70S6K/4EBP1). Silencing acetyl-CoA carboxylase 1 (an enzyme producing malonyl-CoA) normalized malonyl-CoA levels and reactivated mTOR in FASNKD ECs. Mutagenesis unveiled the importance of mTOR K1218 malonylation for angiogenesis. This study unveils a novel role of FASN in metabolite signaling that contributes to explaining the anti-angiogenic effect of FASN blockade

Immunhistochemical analyses of pre-treatment biopsies and corresponding residual tumor tissue

Hintergrund 5-Fluorouracil (5-FU) ist ein wichtiger Bestandteil der Radiochemotherapie (RCT) des lokal fortgeschrittenen Rektumkarzinoms. Thymidylatsynthase (TS) als Hauptwirkort von 5-FU wird als Biomarker zur Responsprädiktion und für die Langzeitprognose disskutiert. In dieser Analyse wurde die TS-Expression in Tumorgewebe von 208 Rektumkarzinompatienten untersucht. Patienten und Methoden 167 Pateinten (cUICC II (26.3%) und III (73.7%)) wurden mit einer neoadjuvanten RCT unter standardisierten Bedingungen entweder mit 50,4Gy und einer 5-FU-Therapie (n=103) oder einer Kombination von 5-FU mit Oxaliplatin (n=64) behandelt. Alle Patienten erhielten im Anschluss eine totale mesorektale Excision (TME). Eine Vergleichsgruppe (n=41) erhielt eine postoperative RCT. TS level aus der prätherapeutischen Biopsie sowie aus dem korresapondierenden Tumorgewebe sowie weitere clinikopathologische Parameter wurden hinsichtlich ihrer prognostischen Bedeutung in univariaten und multivariaten Analysen untersucht. Ergebnisse Patienten mit niedriger TS-Expression in der prätherapeutischen Biopsie haben ein verkürztes tumorspezifisches Gesamtüberleben (CSS) (p=0.015). Während der Follow-Up-Zeit (Median 57 Moante) hatten Patienten mit positivem Nodalstatus und niedriger TS-Expression ein hohes Risiko für ein lokales oder fernmetastatisches Tumorrezidiv (p=0.040). Schlussfolgerung TS stellt einen prognostischen Biomarker im lokal fortgeschrittenen Rektumkarzinom dar, der mit einer ungünstigen Prognose bei geringer Expression assoziiert ist

Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?

Excessive angiogenesis (i.e., the formation of new blood vessels) contributes to different pathologies, among them cancer and ocular disorders. Conversely, dysfunction of endothelial cells (ECs) contributes to cardiovascular complications, as is the case in diabetes. Inhibition of pathologic angiogenesis in blinding eye disease and cancer by targeting growth factors such as vascular endothelial growth factor has become an accepted therapeutic strategy. However, recent studies also unveiled the emerging importance of EC metabolism in controlling angiogenesis. In this overview, we will discuss recent insights in the metabolic regulation of angiogenesis, focusing on the best-characterized metabolic pathways, and highlight deregulation of EC metabolism in cancer and diabetes. We will give an outlook on how targeting EC metabolism can be used for blocking pathologic angiogenesis and for normalizing EC dysfunction.status: publishe